Terms ending in 2038
Every in-force patent on Araxes Pharma LLC's record whose computed term ends in 2038, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,274,093 | Fused Bicyclic Benzoheteroaromatic Compounds and Methods of Use Thereof In force · High confidence | Araxes Pharma LLC | In force | High confidence | |
| US 11,279,689 | 1-(3-(6-(3-Hydroxynaphthalen-1-YL)BENZOFURAN-2-YL)AZETIDIN-1 YL)PROP-2-EN-1-ONE Derivatives and Similar Compounds as Kras G12C Modulators for Treating Cancer In force · High confidence | Araxes Pharma LLC | In force | High confidence | |
| US 10,736,897 | Compounds and Methods of Use Thereof for Treatment of Cancer In force · High confidence | Araxes Pharma LLC | In force | High confidence | |
| US 10,745,385 | Covalent Inhibitors of Kras In force · High confidence | Araxes Pharma LLC | In force | High confidence | |
| US 11,639,346 | Quinazoline Derivatives as Modulators of Mutant Kras, Hras or Nras In force · High confidence | Araxes Pharma LLC | In force | High confidence |
5 of 5 patents shown. Soonest term end first, then patent number.
Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.